Terms: = Prostate cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184
216 results:
1. Stromal-derived MAOB promotes prostate cancer growth and progression.
Pu T; Wang J; Wei J; Zeng A; Zhang J; Chen J; Yin L; Li J; Lin TP; Melamed J; Corey E; Gao AC; Wu BJ
Sci Adv; 2024 Feb; 10(6):eadi4935. PubMed ID: 38335292
[TBL] [Abstract] [Full Text] [Related]
2. Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways.
Ciummo SL; Sorrentino C; Fieni C; Di Carlo E
J Exp Clin Cancer Res; 2023 Dec; 42(1):336. PubMed ID: 38087324
[TBL] [Abstract] [Full Text] [Related]
3. Adaptor proteins mediate cxcr4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth.
Govindarajan B; Sbrissa D; Pressprich M; Kim S; Rishi AK; Vaishampayan U; Cher ML; Chinni SR
Sci Rep; 2023 Nov; 13(1):20634. PubMed ID: 37996444
[TBL] [Abstract] [Full Text] [Related]
4. Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p-STAT3 in prostate cancer.
Wang L; Lyu C; Stadlbauer B; Buchner A; Nößner E; Pohla H
Prostate; 2024 Feb; 84(2):131-147. PubMed ID: 37828768
[TBL] [Abstract] [Full Text] [Related]
5. CXCL12-cxcr4/CXCR7 Axis in cancer: from Mechanisms to Clinical Applications.
Yang Y; Li J; Lei W; Wang H; Ni Y; Liu Y; Yan H; Tian Y; Wang Z; Yang Z; Yang S; Yang Y; Wang Q
Int J Biol Sci; 2023; 19(11):3341-3359. PubMed ID: 37497001
[TBL] [Abstract] [Full Text] [Related]
6. Stromal cell-derived factor 1 (SDF-1) increases the number of telocytes in ex vivo and in vitro assays.
Sanches BDA; Tamarindo GH; da Silva ADT; Amaro GM; Dos Santos Maldarine J; Dos Santos VA; Guerra LHA; Baraldi CMB; Góes RM; Taboga SR; Carvalho HF
Histochem Cell Biol; 2023 Nov; 160(5):419-433. PubMed ID: 37474667
[TBL] [Abstract] [Full Text] [Related]
7. A cxcr4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.
Robinson T; Escara-Wilke J; Dai J; Zimmermann J; Keller ET
Prostate; 2023 Sep; 83(13):1247-1254. PubMed ID: 37244751
[TBL] [Abstract] [Full Text] [Related]
8. Interstitial fluid flow contributes to prostate cancer invasion and migration to bone; study conducted using a novel horizontal flow bioreactor.
Jasuja H; Jaswandkar SV; Katti DR; Katti KS
Biofabrication; 2023 Mar; 15(2):. PubMed ID: 36863017
[TBL] [Abstract] [Full Text] [Related]
9. The Role of Cytokines in the Metastasis of Solid Tumors to the Spine: Systematic Review.
Łabędź W; Przybyla A; Zimna A; Dąbrowski M; Kubaszewski Ł
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835198
[TBL] [Abstract] [Full Text] [Related]
10. CXCR7 as a novel therapeutic target for advanced prostate cancer.
Gritsina G; Yu J
Oncogene; 2023 Mar; 42(11):785-792. PubMed ID: 36755058
[TBL] [Abstract] [Full Text] [Related]
11. Dynamics of cxcr4 positive circulating tumor cells in prostate cancer patients during radiotherapy.
Klusa D; Lohaus F; Franken A; Baumbach M; Cojoc M; Dowling P; Linge A; Offermann A; Löck S; Hušman D; Rivandi M; Polzer B; Freytag V; Lange T; Neubauer H; Kücken M; Perner S; Hölscher T; Dubrovska A; Krause M; Kurth I; Baumann M; Peitzsch C
Int J Cancer; 2023 Jun; 152(12):2639-2654. PubMed ID: 36733230
[TBL] [Abstract] [Full Text] [Related]
12. Targeting HIC1/TGF-β axis-shaped prostate cancer microenvironment restrains its progression.
Wu T; Wang W; Shi G; Hao M; Wang Y; Yao M; Huang Y; Du L; Zhang X; Ye D; Bian X; Wang J
Cell Death Dis; 2022 Jul; 13(7):624. PubMed ID: 35853880
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive characterization of the prostate tumor microenvironment identifies cxcr4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I; Fotakis G; Offermann A; Goveia J; Daum S; Salcher S; Noureen A; Timmer-Bosscha H; Schäfer G; Walenkamp A; Perner S; Beatovic A; Moisse M; Plattner C; Krogsdam A; Haybaeck J; Sopper S; Thaler S; Keller MA; Klocker H; Trajanoski Z; Wolf D; Pircher A
Mol Cancer; 2022 Jun; 21(1):132. PubMed ID: 35717322
[TBL] [Abstract] [Full Text] [Related]
14. pH-sensitive nanoliposomes for passive and CXCR-4-mediated marine yessotoxin delivery for cancer therapy.
Vieira AM; Silvestre OF; Silva BF; Ferreira CJ; Lopes I; Gomes AC; Espiña B; Sárria MP
Nanomedicine (Lond); 2022 Apr; 17(10):717-739. PubMed ID: 35481356
[No Abstract] [Full Text] [Related]
15. Role of Resveratrol as Radiosensitizer by Targeting cancer Stem Cells in Radioresistant prostate cancer Cells (PC-3).
El-Benhawy SA; Morsi MI; Fahmy EI; Soula MA; Khalil FAZF; Arab AR
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3823-3837. PubMed ID: 34967561
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic significance of SDF-1 chemokine and its receptors cxcr4 and CXCR7 involved in EMT of prostate cancer.
Parol-Kulczyk M; Gzil A; Ligmanowska J; Grzanka D
Cytokine; 2022 Feb; 150():155778. PubMed ID: 34920230
[TBL] [Abstract] [Full Text] [Related]
17. Bone marrow mesenchymal stem cells promote the progression of prostate cancer through the SDF-1/cxcr4 axis in vivo and vitro.
Luo F; Su Y; Zhang Z; Li J
Clin Transl Oncol; 2022 May; 24(5):892-901. PubMed ID: 34855138
[TBL] [Abstract] [Full Text] [Related]
18. Triterpenoid ursolic acid drives metabolic rewiring and epigenetic reprogramming in treatment/prevention of human prostate cancer.
Li S; Wu R; Wang L; Dina Kuo HC; Sargsyan D; Zheng X; Wang Y; Su X; Kong AN
Mol Carcinog; 2022 Jan; 61(1):111-121. PubMed ID: 34727410
[TBL] [Abstract] [Full Text] [Related]
19. The Embryonic Key Pluripotent Factor NANOG Mediates Glioblastoma Cell Migration via the SDF1/cxcr4 Pathway.
Sánchez-Sánchez AV; García-España A; Sánchez-Gómez P; Font-de-Mora J; Merino M; Mullor JL
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638956
[TBL] [Abstract] [Full Text] [Related]
20. Preferential interaction of platelets with prostate cancer cells with stem cell markers.
Rudzinski JK; Govindasamy NP; Asgari A; Saito MS; Lewis JD; Jurasz P
Thromb Res; 2021 Oct; 206():42-51. PubMed ID: 34403851
[TBL] [Abstract] [Full Text] [Related]
[Next]
